drugset / Trial / NCT00231998

Extension Study of Pimecrolimus Cream in Pediatric Patients With Atopic Dermatitis

NCT00231998

Phase 3 Completed 240 enrolled Novartis
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Pimecrolimus, which is an ascomycin derivative, is an anti-inflammatory non-steroidal agent. In this study, the long-term safety and efficacy of Pimecrolimus cream will be evaluated in Japanese pediatric patients with atopic dermatitis. This study is a 6-month extension study following core study. THIS STUDY IS NOT ENROLLING PATIENTS IN THE UNITED STATES

Timeline

Start
2004-05
Primary completion
Completion
2005-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Pimecrolimus Small molecule 1 %

Indications